Paul Buckman

Mr. Buckman currently serves on the Board of Directors for a number of medical technology companies including Xtant Medical, a medical technology company serving the needs of orthopedic and neurological surgeons; Ablative Solutions Inc., founded in 2011 to address the unmet clinical need of systemic hypertension; Aortica, a company dedicated to advancing the treatment of complex abdominal aortic aneurysm (AAA) disease; Caisson Interventional, a privately held clinical-stage medical device company designing and developing a novel percutaneous mitral valve replacement system; NeuroOne; and BioStar Ventures. Previously, Mr. Buckman also held CEO roles at Conventus Orthopaedics, a developer of a novel 3-dimensional fracture fixation technology; SentreHeart (continues as Director), Pathway Medical Technologies (sold to Bayer Healthcare in 2011), and Devax, Inc. (sold to Biosensors International). From 2004 through 2006, Mr. Buckman served as President of the Cardiology Division of St. Jude Medical, Inc. Prior to joining St. Jude Medical, Mr. Buckman served as Chairman of the Board and CEO of ev3, LLC, a Minnesota-based cardiovascular device company that Mr. Buckman co-founded and later acquired by Covidien for $2.5B. He also previously held the position of President of the Cardiology Division of Boston Scientific. Mr. Buckman received a B.A. degree in Business Administration and an MBA degree from Western Michigan University.